K
Kon-Siong G. Jie
Researcher at Maastricht University
Publications - 22
Citations - 1372
Kon-Siong G. Jie is an academic researcher from Maastricht University. The author has contributed to research in topics: Multiple myeloma & Osteocalcin. The author has an hindex of 13, co-authored 21 publications receiving 1222 citations.
Papers
More filters
Journal ArticleDOI
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Henk M. Lokhorst,Bronno van der Holt,Sonja Zweegman,Edo Vellenga,Sandra Croockewit,Marinus H. J. van Oers,Peter A. von dem Borne,Pierre W. Wijermans,R. Schaafsma,Okke de Weerdt,Shulamiet Wittebol,Michel Delforge,Henriette Berenschot,Gerard M. J. Bos,Kon-Siong G. Jie,Harm Sinnige,Marinus van Marwijk-Kooy,P. Joosten,Monique C. Minnema,Rianne Ammerlaan,Pieter Sonneveld +20 more
TL;DR: Thalidomide significantly improved overall response rate as well as quality of the response before and after high dose melphalan, and prolonged progression free from median 25 months to 34 months (P < .001).
Journal ArticleDOI
Effect of food composition on vitamin K absorption in human volunteers
TL;DR: The bioavailability of membrane-bound phylloquinone is extremely poor and may depend on other food components, notably fat, which may lead to a revision of the recommended daily intake for vitamin K.
Journal ArticleDOI
Vitamin K Status and Bone Mass in Women With and Without Aortic Atherosclerosis: A Population-Based Study
TL;DR: The finding that in atherosclerotic women vitamin K status is associated with bone mass supports the hypothesis that vitamin K Status affects the mineralization processes in both bone and in atheosclerotic plaques.
Journal ArticleDOI
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
Lieke H. van der Helm,Canan Alhan,Pierre W. Wijermans,Marinus van Marwijk Kooy,R. Schaafsma,Bart J. Biemond,Aart Beeker,Mels Hoogendoorn,Bastiaan P. van Rees,Okke de Weerdt,Jurgen Wegman,Ward J. Libourel,Sylvia A. Luykx-de Bakker,Monique C. Minnema,Rolf E. Brouwer,Fransien Croon-de Boer,Matthijs Eefting,Kon-Siong G. Jie,Arjan A. van de Loosdrecht,Jan Koedam,Nic J. G. M. Veeger,Edo Vellenga,Gerwin Huls +22 more
TL;DR: Routine administration of azacitidine to patients with variable risk groups of MDS, CMML and AML is feasible, and subgroups with distinct efficacy of azACitidine treatment can be identified.
Journal ArticleDOI
Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial
Pascale Notten,Arina J. ten Cate-Hoek,Carsten W. K. P. Arnoldussen,Rob H. W. Strijkers,André A. E. A. de Smet,Lidwine W. Tick,Marlène H. W. van de Poel,Otmar R. M. Wikkeling,Louis-Jean Vleming,Ad Koster,Kon-Siong G. Jie,Esther M. G. Jacobs,Harm P. Ebben,Michiel Coppens,Irwin M. Toonder,Hugo ten Cate,Cees H. A. Wittens,Cees H. A. Wittens +17 more
TL;DR: This study showed that additional ultrasound-accelerated catheter-directed thrombolysis does not change the risk of post-thrombotic syndrome 1 year after acute iliofemoral deep-vein thrombosis compared with standard therapy alone.